[Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer].

Gan to kagaku ryoho. Cancer & chemotherapy ·Vol. 13 ·No. 8 ·1986-08-00 ·Pages 2532-7

Mitomi T, Kyoji-Ogoshi

Abstract

The effects of PSK in combination with Mitomycin C, Adriamycin and Tegafur were studied in 168 patients who underwent gastrectomy for gastric cancer. The study group receiving PSK showed improved survival and there was a significant difference in the estimated survival. An improved survival rate was also shown at stages III and IV, in the group given an FAM regimen and in the group with well differentiated adenocarcinoma.

MeSH Terms

Adult Aged Antibiotics, Antineoplastic/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Combined Modality Therapy Doxorubicin/administration & dosage Female Gastrectomy Humans Male Middle Aged Mitomycin Mitomycins/administration & dosage Postoperative Care Prognosis Proteoglycans/therapeutic use Stomach Neoplasms/drug therapy,mortality,surgery Tegafur/administration & dosage

Chemicals

Antibiotics, Antineoplastic Mitomycins Proteoglycans Tegafur polysaccharide-K Mitomycin Doxorubicin

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Mitomi T

Kyoji-Ogoshi

Article Info

Journal

Gan to kagaku ryoho. Cancer & chemotherapy

Abbr.

Gan To Kagaku Ryoho

ISSN

0385-0684

Published

1986-08-00

Pages

2532-7

Language

jpn

Region

Japan

NLM ID

7810034

Subset

External Links

PubMed source

Analysis Services

[Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer].

Contact

WeChat Official Account